ecancermedicalscience最新文献

{"title":"Low body mass index demonstrates satisfactory specificity for diagnosing malnutrition and is associated with longer hospitalization in patients with gastrointestinal or head and neck cancer: a prospective cohort study.","authors":"Camilla Horn Soares, Giovanna Potrick Stefani, Laura Machado Scott, Mariana Scortegagna Crestani, Thais Steemburgo","doi":"10.3332/ecancer.2025.1846","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1846","url":null,"abstract":"<p><strong>Background: </strong>The main causes of malnutrition in patients with gastrointestinal and head and neck cancers include metabolic alterations determined by the tumour and its stage, as well as low food intake caused by the disease itself and the effects of antineoplastic treatment. In the hospital environment, nutritional markers, such as body mass index (BMI), handgrip strength (HGS) and calf circumference (CC), can be used to identify malnutrition early, ensuring individualized and specific nutritional intervention. However, few studies have evaluated the individual performance of nutritional indicators in diagnosing malnutrition in a cancer setting. We aimed to assess the ability of these nutritional indicators to accurately diagnose malnutrition and their association with length of hospital stay (LOS) in patients with cancer.</p><p><strong>Methods: </strong>This cohort study prospectively evaluated 171 patients with gastrointestinal or head and neck cancer. Nutritional status was assessed within 48 hours of hospital admission using BMI, CC and HGS as well as two reference standards: subjective global assessment (SGA) and patient-generated SGA (PG-SGA). The accuracy of each nutritional indicator was measured by the area under the receiver operating characteristic curve (AUC) compared with the reference standards. Multiple logistic regression analysis, adjusted for confounders, was used to determine whether malnutrition was associated with LOS.</p><p><strong>Results: </strong>Of 171 patients, 59.1% had low CC, 46.2% had low HGS and 13.5% had low BMI. The SGA and PG-SGA scores indicated malnutrition in 57.4% and 87.2% of patients, respectively. All nutritional indicators had poor accuracy in diagnosing malnutrition (AUC < 0.70). However, compared with SGA and PG-SGA, low BMI had satisfactory specificity (>80%) and was associated with 1.79 times higher odds of LOS ≥ 6 days. Malnutrition diagnosed by SGA and PG-SGA increased the odds of LOS ≥ 6 days by 3.60-fold and 2.78-fold, respectively.</p><p><strong>Conclusion: </strong>Low BMI showed adequate specificity for diagnosing malnutrition and was associated with longer LOS in patients with gastrointestinal or head and neck cancer. Further research is needed to explore how improved screening, interventions and nutritional support could reduce malnutrition rates in cancer patients.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1846"},"PeriodicalIF":1.2,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upfront surgery versus chemotherapy neoadjuvant in the survival of patients with locally advanced gastric signet-ring-cell adenocarcinoma. A scoping review.","authors":"Erick R Vásquez-Jaico, Edgar Fermín Yan-Quiroz, Nicol Bonilla-Feria, Mery Nancy Villarreal Gonzalez, Luis Salas Guzmán, Gustavo Adolfo Vásquez-Tirado, Victor Serna-Alarcon","doi":"10.3332/ecancer.2025.1843","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1843","url":null,"abstract":"<p><strong>Background: </strong>Recent research suggests that neoadjuvant chemotherapy is not effective for gastric cancer with signet ring cells.</p><p><strong>Objective: </strong>The present study performs a scoping review of research that seeks to determine whether neoadjuvant chemotherapy is more effective than upfront surgery in the survival of locally advanced signet ring gastric adenocarcinoma.</p><p><strong>Design: </strong>Online databases such as Pubmed, scopus and embase were used to identify articles from the last 20 years that used survival, as an initial or secondary outcome variable, after upfront surgery or neoadjuvant chemotherapy as initial treatment in locally advanced gastric signet ring cells adenocarcinoma.</p><p><strong>Results: </strong>After a systematic selection process, five primary studies were selected that evaluated neoadjuvant chemotherapy compared to primary surgery.</p><p><strong>Conclusion: </strong>Neoadjuvant chemotherapy does not appear to have greater benefit than initial surgery in gastric adenocarcinoma with locally advanced sign ring cells, it is necessary to define which is the most appropriate qt scheme for adenocarcinoma with sign ring cells, clinical trials type studies are required to improve the evidence. Finally, a national clinical practice guide is required as an interpretative map for the management of gastric cancer which may be appropriate as a first step to know the reality.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1843"},"PeriodicalIF":1.2,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis.","authors":"Chalothorn Wannaphut, Phuuwadith Wattanachayakul, Sakditad Saowapa, Ben Ponvilawan, Manasawee Tanariyakul, Jakrin Kewcharoen, Pitchaporn Yingchoncharoen, Thanathip Suenghataiphorn, Noppawit Aiumtrakul, Jared Acoba","doi":"10.3332/ecancer.2025.1844","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1844","url":null,"abstract":"<p><strong>Background/objectives: </strong>Sodium-glucose-co-transporter-2 (SGLT2) inhibitors have shown benefit in reducing cardiovascular disease outcomes in diabetes patients. Anthracycline therapy is associated with a risk of cardiomyopathy. However, the impact of SGLT2 inhibitors in the prevention of cardiomyopathy and heart failure in cancer patients undergoing anthracycline treatment remains unclear. Thus, we conducted a systematic review and meta-analysis to explore the effect of the prevention of cardiovascular outcomes in patients with cancer and diabetes who had received anthracycline therapy.</p><p><strong>Methods: </strong>We systematically reviewed Medline and EMBASE databases from inception to January 2024 for studies focusing on cancer patients with a history of anthracycline therapy. Eligible studies had to report relative risk (RR) with 95% confidence intervals (CIs) for the clinical endpoints of mortality outcomes and the risk of heart failure exacerbation, comparing cohorts with and without SGLT2 inhibitor use.</p><p><strong>Results: </strong>Our study included four retrospective cohort studies in the meta-analysis (<i>n</i> = 6,708, 24% received SGLT2). There was significantly lower all-cause mortality in the SGLT2 inhibitors group (pooled RR of 0.52, 95% CI 0.35-0.77, <i>I</i> ² 64%). However, there were no differences in the risk of heart failure exacerbation (pooled RR of 0.67, 95% CI 0.39-1.14, <i>I</i> ² 17%).</p><p><strong>Conclusion: </strong>Our study found that anthracycline-treated cancer patients using SGLT2 inhibitors experienced lower all-cause mortality compared to the control group. A randomised clinical trial is necessary to further elucidate these findings.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1844"},"PeriodicalIF":1.2,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of cancer care pathways at Wajir County, Kenya: patient perspectives.","authors":"Fatuma Affey, Dabo Galgalo Halake, Grace Muira Wainaina, Hussein Ali Osman, James G Ndukui, Houda Abdourahman, Omar Abdihamid","doi":"10.3332/ecancer.2025.1841","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1841","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cancer represents a major public health issue with substantial morbidity and mortality in low-resource settings such as Kenya. This study focuses on Wajir County in northern Kenya, a region with limited cancer care infrastructure and high unmet needs. Despite recent efforts to decentralize cancer care in Kenya, including establishing regional cancer centres in Garissa, Nakuru, and Mombasa, access to screening, diagnostics, and treatment remains constrained, particularly in rural areas. The absence of comprehensive cancer care pathways and a specialized oncology workforce in Wajir County exacerbates challenges in early detection, treatment, and palliative care. The study evaluated the availability of cancer care services at Wajir County Referral Hospital (WCRH), including screening, diagnostic services, treatment modalities, and referral systems. The study further explores the gaps in cancer care, focusing on patient perspectives, and proposes potential solutions to address these challenges.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study used mixed-methods (qualitative and quantitative) methods to understand cancer care from the perspective of patients at WCRH. It involved adult patients (over 18) with a confirmed cancer diagnosis who were receiving treatment or follow-up care between February and April 2024. Data were gathered through interviews and surveys, with research assistants helping with language translation and community navigation. The study collected information on demographics, cancer types, and prevalence rates, which were analysed using descriptive statistics. The qualitative data focused on patients' experiences with cancer awareness, treatment, and care gaps, and were analysed for common themes. Ethical approval was obtained, and informed consent was given by all participants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study involved 25 cancer patients (12 males, 13 females) receiving treatment at WCRH. The most common cancers were esophageal (44%), cervical (28%), breast (24%), and prostate (8%). Delays in diagnosis were significant, with 12% of patients waiting over 6 years, 24% waiting 4-6 years, and 40% waiting 1-3 years before seeking care. Most diagnoses were made at WCRH (64%), with others diagnosed at the Garissa Cancer Centre (22%) or in Nairobi (20%). Diagnostic tools available at WCRH included pap smears, mammograms, PSA tests, ultrasound, CT scans, and biopsies. However, access to these tools was limited, with barium swallow (32%) being the most frequently used for esophageal cancer, followed by pap smears, biopsies, and ultrasound (16% each). Patient awareness of cancer screening was higher for cervical (68%) and breast cancer (60%) but lower for prostate cancer (32%) and esophageal cancer (4%). Despite awareness, only 8% had previously undergone screening. Regarding treatment, most patients (80%) were aware of surgical options, while fewer knew about chemotherapy (28%) or palliative care (12%). ","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1841"},"PeriodicalIF":1.2,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glassy cell carcinoma of the uterine cervix: a rare entity and literature review.","authors":"Tenazoa-Villalobos José Richard, Yan-Quiroz Edgar Fermín, Ordoñez-Chinguel Augusto, Prado-Cucho Sofia Leonor, Miranda-Narro Adesman Isac, Vladimir Villoslada-Terrones","doi":"10.3332/ecancer.2025.1842","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1842","url":null,"abstract":"<p><p>Glassy cell carcinoma is an extremely rare entity that occurs in 1% to 2% of all cases of cervical cancer, affects young women with greater predisposition, is related to poor prognosis, and distant metastasis. It correlates strongly with the presence of high-risk human papillomavirus (serotypes 16, 18 and 31) and histologically manifests as ground-glass cells, cytosol with vast granular and dense chromatin with large nuclei and protruding nucleoli. We present a 51-year-old woman who was diagnosed with glassy cell carcinoma of the cervix (before the latest edition of the World Health Organisation classification of tumours) in FIGO stage IB1 that was managed with radical hysterectomy and bilateral pelvic lymph node dissection, whose pathological result shows infiltration of the upper third of the vagina, changing the staging to FIGO IIA-1. She received adjuvant concurrent radiotherapy/chemotherapy with a good response, subsequent controls without signs of recurrence and remained currently alive.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1842"},"PeriodicalIF":1.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine Tertiary Government Hospital.","authors":"Carl Arenos, Steven Lim, Andreu Lominoque, Isabela Reveldez, Angeli Sison-Dimaano, Nehar Pagandaman, Vincent Tatoy, Timothy Uy, Michael San Juan","doi":"10.3332/ecancer.2025.1840","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1840","url":null,"abstract":"<p><strong>Background and objectives: </strong>Human epidermal receptor 2 (HER2)-low breast cancer, characterised by specific immunohistochemistry (IHC) scores (+1 or +2) or negative fluorescence in-situ hybridiszation (FISH), has unique biological traits, therapeutic outcomes and prognosis. Recent studies highlight the effectiveness of Trastuzumab-Deruxtecan (T-Dxd) for HER2-low patients. This study seeks to deepen understanding of HER2 negative and low patients for tailored treatment by determining the 3-year disease-free survival (DFS) rates and prognostic variables of different subsets of HER2 negative (HER2 0) and HER2-low breast cancer patients (HER2 +1, HER2 +2 and HER2 FISH negative).</p><p><strong>Methodology: </strong>We analysed the records of 138 patients with non-metastatic breast cancer, exhibiting HER2 IHC 0, +1 or +2/FISH negative. Data on 3-year DFS in months, age, stage (early stage versus locally advanced) and menopausal status were collected. Kaplan-Meier survival curves were used to plot 3-year DFS, while Cox Proportional Analysis assessed the prognostic significance of age and menopausal status in the HER2-low population.</p><p><strong>Results: </strong>Three-year DFS for HER2 0 was 84.4%, HER2 +1 was 81.8% and HER2 +2/FISH negative was 52.9%, displaying statistically significant differences (<i>p</i> = 0.00012). Subgroup analyses revealed consistently worse DFS for HER2 +2/FISH negative patients in both early and advanced stages (<i>p</i> = 0.0042, 0.0057). Cox proportional analysis showed a recurrence hazard ratio of 4.0-4.5 for HER2 +2/FISH negative patients. Among prognostic factors, post-menopausal status correlated with a decreased risk of recurrence (HR 0.4387), signifying a 56.13% lower recurrence risk compared to pre-menopausal patients (<i>p</i> = 0.00723). On the other hand, patient age was not correlated with a reduced risk of recurrence (HR 0.97; <i>p</i> = 0.0544).</p><p><strong>Conclusion: </strong>This study reveals a worse 3-year DFS in HER2 +2/FISH negative patients across both early and advanced disease stages. The findings highlight the prognostic importance of HER2-low status and may guide future therapeutic strategies, including the use of targeted therapies like T-Dxd in non-metastatic patients.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1840"},"PeriodicalIF":1.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in gastrointestinal cancer burden in Zimbabwe: 10-year retrospective study 2009-2018.","authors":"Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Margaret Borok, Vincent Aketch Nyangwara, Pageneck Chikondowa, Marie Hidjo Madeleine, Collen Masimirembwa, Onesai Chihaka, Edith Matsikidze, Charley Jang, Kevin Grimes","doi":"10.3332/ecancer.2025.1839","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1839","url":null,"abstract":"<p><strong>Background: </strong>As one of the non-communicable diseases, cancer will overtake communicable, maternal, neonatal and nutritional diseases combined as the leading cause of mortality by 2040. Gastrointestinal (GI) cancers are predicted to increase by over 50% in the next 20 years, with a higher incidence in developing countries. In this study, we describe the national GI cancer trends in Zimbabwe using the annual reports from the Zimbabwe National Cancer Registry (ZNCR) from 2009 to 2018.</p><p><strong>Methods: </strong>Demographic data and incidence of GI cancer subtypes were collected and analysed from the ZNCR annual reports from 2009 to 2018. Age standardised rates (ASRs) for each GI cancer subtype were calculated and simple trend analysis was performed over the 10-year study period.</p><p><strong>Results: </strong>In total, 10,859 new GI cancer cases were reported during the study period, accounting for 17.2% of all cancers in Zimbabwe and 55% of these were males. The most prevalent GI cancers were oesophageal, liver, gastric, colon and rectal malignancies. In males, on average the incidence of ASR of oesophageal, liver and gastric cancer increased annually by 14.7%, 17% and 16%, respectively. In females, on average the ASR of oesophageal, liver and gastric cancer increased annually by 27.2%; 18% and 13%, respectively. Overall, one in ten new cases of oesophageal cancer were diagnosed in patients under 45 years of age and for liver cancer, one in four new male cases were diagnosed below the age of 45 years.</p><p><strong>Conclusion: </strong>Zimbabwe faces an increasing trend in all GI cancer subtype incidence over the decade reviewed. The rate of increase in oesophageal and gastric cancers in females was particularly high and the male-to-female ratio observed requires further etiological studies. The increasing rate of young GI cancer patients requires both education regarding risk factors and national screening policies that are tailored to the Zimbabwean population's characteristics and context.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1839"},"PeriodicalIF":1.2,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of cyclooxygenase-2 (COX-2) in epithelial ovarian cancers in an Indigenous African population of Kano, Nigeria.","authors":"Jimoh Ajanaku Abdulrazaq, Mohammed Abdullahi, Nzekwe Patric Chim, Richard Kelechi Samuel","doi":"10.3332/ecancer.2025.1838","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1838","url":null,"abstract":"<p><p>The high case-fatality of epithelial ovarian cancer (EOC) stems from the absence of recognisable premalignant lesion, lack of effective screening, advanced stage at presentation, high recurrence and COX-2 over-expression. Expression of COX-2 in EOCs is associated with unfavorable survival outcomes. In Nigeria, younger age affectation, rising incidence and poor survival outcomes of EOC provide the driving forces for researchers in terms of screening, prevention and targeted therapy.</p><p><strong>Methods: </strong>All the 52 EOC cases over a 5-year period were included, but only 48 formalin-fixed paraffin-embedded tissue blocks were sectioned and stained with COX-2 antibody. COX-2 expression was scored for distribution (no cells = 0, 1%-10% = 1, 11%-50% = 2, 51%-80% = 3, 81%-100% = 4) and intensity (no stain = 0; weak = 1; moderate = 2, strong = 3). The immunoreactive score (IRS) is a product of intensity (I) and distribution (D) as: 9-12 strongly +, 5-8 moderately +, 1-4 weakly + and 0 negative. Over-expression of COX-2 is an IRS of 5-12. Outcomes were statistically evaluated with clinicopathological data.</p><p><strong>Results: </strong>EOC cases have a mean age of 50.0 years, and peaked in the 6th decade. High-grade serous carcinoma (HGSC) accounted for the majority (50%), followed by low-grade serous carcinoma and mucinous carcinomas each at 17.3%. High-grade carcinomas accounted for 61.5% of cases. Over-expression of COX-2 was observed in 52.1% of the cases with significant associations between COX-2 expression and high-grade EOC, type II EOC or HGSC but not with the other histological sub-type or age.</p><p><strong>Conclusion: </strong>More than one-third of EOCs occurred ≤50 years and more than half of EOCs over-expressed COX-2. There were significant statistical associations between COX-2 over-expression and grade, type II tumours or HGSC indicating that it may influence the outcomes of EOC with possible variation in tumour type and grade.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1838"},"PeriodicalIF":1.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysing the clinical outcomes between FIGO 2009 and 2023 staging for endometrial cancer-a single institution retrospective study.","authors":"Divya P Vuppu, Anupama Rajanbabu, Indu R Nair, Anjaly S Nair, Ajay Sasidharan, Kalavagunta Sruthi, Keechilat Pavithran, Reshma Jeladharan","doi":"10.3332/ecancer.2025.1836","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1836","url":null,"abstract":"<p><p>The latest International Federation of Gynaecology and Obstetrics (FIGO) staging for endometrial cancer incorporated molecular profiles and histopathological factors into the basic staging framework. This study was done to determine its implications when applied in real-world clinical practice. The main objectives were to analyse the stage shifts and determine the stage-wise 3-year overall survival (OS) and disease-free survival (DFS) between the two staging systems. It was a single-institution retrospective study that included all Endometrial cancer patients who underwent surgery between January 2015 and June 2021. Cases that underwent primary or incomplete surgery elsewhere and cases with histological types of cancer not included in FIGO 2023 staging were excluded from the study. All patients were staged according to FIGO 2009 and 2023 staging for endometrial cancer. This study found most stage shifts among stage I cases; based on aggressive histology, 33.8% (<i>n</i> = 65/192) of cases in stage IA and IB upstaged to stage IIC (2023). Meanwhile, among the advanced stages, most were downstaged, i.e., from stage IIIA to stage IA3 0.6% (<i>n</i> = 1/15), from stage IVB to stage IIIB2 (2023), i.e., 32% (<i>n</i> = 8/25). This study failed to show any significant differences in the stage-wise 3-year OS rate and DFS rate between the two staging systems. The present study provided preliminary data on the latest FIGO endometrial staging system. Due to the addition of subgroups based on prognostic factors, most upstages occurred in the early stages, while downshifts occurred in the advanced stages. There was no clinical difference in the 3-year OS and DFS rates.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1836"},"PeriodicalIF":1.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An evaluation of the adequacy of Indian national and state essential medicines lists (EMLs) for palliative care medical needs-a comparative analysis.","authors":"Disha Agrawal, Divya Shrinivas, Parth Sharma, Muttacaud Ramakrishnan Rajagopal, Arun Ghoshal, Siddhesh Zadey","doi":"10.3332/ecancer.2025.1837","DOIUrl":"https://doi.org/10.3332/ecancer.2025.1837","url":null,"abstract":"<p><strong>Objectives: </strong>Essential medicines lists (EMLs) guide the public sector procurement and supply of medications to impact access to adequate and appropriate palliative care drugs. This study evaluates the adequacy of India's national and sub-national EMLs that can directly impact palliative care for 5.4 million patients.</p><p><strong>Methods: </strong>In this qualitative document review, we compared Indian national, and state EMLs acquired from official government websites with the International Association for Hospice and Palliative Care (IAHPC) EML recommendations. We analysed data on the indication and formulation of drugs under the different categories of formulations present (all, some and no), and drugs absent. Literature review and inputs from palliative care experts provided alternatives of absent medications to assess the adequacy of lists in managing the symptoms listed by IAPHC.</p><p><strong>Results: </strong>We analysed 3 national and 27 state lists for 33 recommended drugs. The Central Government Health Services list had the maximum availability of all formulations of drugs (16 [48%]) nationally. Among states and union territories, the Delhi EML was the closest to IAHPC with 17 (52%) drugs with all formulations present. Karnataka had the most incomplete EML with only 3 (9%) drugs with all formulations present. No EML had all the recommended formulations of morphine. In one national and seventeen state EMLs, oral morphine was absent.</p><p><strong>Conclusion: </strong>While Indian EMLs lack drugs for palliative care when compared with the IAHPC EML, symptom management is adequate. There is a need for countries with limited resources to modify the IAPHC list for their settings.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1837"},"PeriodicalIF":1.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}